COMPASS Pathways plc

Listed Company

CMPSCIK 0001816590NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsX0GBFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-287.90M

Total Assets

$210.35M

Equity

$-52.85M

Shares Out

128.92M

Op. Cash Flow

$-157.24M

Business

Compass Pathways plc is a biotechnology company focused on accelerating patient access to evidence-based innovations in mental health. It develops COMP360, a pharmaceutical‑grade crystalline psilocybin formulation, and delivers associated psychological support and digital tools used in its clinical protocols. Its operations encompass clinical development (Phase 2 and Phase 3 trials) across treatment‑resistant depression, PTSD and other indications, investigator‑initiated and mechanistic studies, manufacturing partnerships and digital initiatives. The company conducts multinational trials and collaborates with academic centers, healthcare delivery partners and CDMOs, distributing investigational product through clinical sites and Centers of Excellence.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	118	119	88	65	44
General and administrative	61	59	49	45	39
Total operating expenses	179	178	137	110	83
LOSS FROM OPERATIONS:	−179	−178	−137	−110	−83
Fair value change of warrant liabilities	−123	0	—	—	—
Benefit from R&D tax credit	4	21	13	14	10
Interest income	7	8	5	—	—
Interest expense	−5	−4	−2	—	—
Foreign exchange gains (losses)	3	−1	4	821,000	2
Other income	1	823,000	255,000	—	—
Total other (expense) income, net	−111	25	19	19	12
Loss before income taxes	−290	−154	−118	−91	−72
Income tax benefit (expense)	2	−2	−780,000	−408,000	−199,000
Net loss	−288	−155	−119	−92	−72
Net loss per share attributable to ordinary shareholders - basic (in dollars per share)	−3.08	−2.3	−2.32	−2.16	−1.79
Net loss per share attributable to ordinary shareholders - diluted (in dollars per share)	−3.08	−2.3	−2.32	−2.16	−1.79
Weighted average ordinary shares outstanding - basic (in shares)	94	67	51	42	40
Weighted average ordinary shares outstanding - diluted (in shares)	94	67	51	42	40
Foreign exchange translation adjustment	1	732,000	−59,000	—	—
Comprehensive loss	−286	−154	−119	−117	−77

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	150	165	220	143	273
Restricted cash	379,000	389,000	440,000	175,000	104,000
Prepaid expenses and other current assets	42	36	—	—	—
Total current assets	191	201	261	192	295
Operating lease right-of-use assets	3	2	4	2	4
Deferred tax assets	4	4	3	2	766,000
Long-term prepaid expenses and other assets	12	7	7	1	213,000
Total assets	210	214	276	197	301
Accounts payable	15	12	6	5	3
Accrued expenses and other liabilities	9	14	11	9	10
Debt, current portion	18	6	0	—	—
Operating lease liabilities - current	2	2	2	2	2
Warrant liabilities	204	93	—	—	—
Total current liabilities	248	34	20	16	15
Debt, non-current portion	14	25	29	—	—
Operating lease liabilities - non-current	1	303,000	2	418,000	1
Total liabilities	263	59	50	16	16
Commitments and contingencies (Note 14)	—	—	—	—	—
Ordinary shares, 0.008 par value; 96,085,785 and 68,552,215 shares authorized, issued and outstanding at December 31, 2025 and 2024, respectively	973,000	702,000	635,000	—	—
Additional paid-in capital	784	705	622	459	445
Accumulated other comprehensive loss	−15	−16	−17	−17	9
Accumulated deficit	−823	−535	−380	−261	−170
Total shareholders' (deficit)/equity	−53	155	226	181	284
Total liabilities and shareholders' (deficit)/equity	210	214	276	197	301

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	216,000	233,000	242,000	—	—
Non-cash interest	1	1	636,000	0	0
Non-cash gain (loss) on foreign currency remeasurement	−1	755,000	−3	1	22,000
Non-cash share-based compensation	14	20	17	13	9
Non-cash lease expenses	2	2	2	2	2
Transaction costs allocated to warrants	6	0	—	—	—
Prepaid expenses and other current assets	−3	3	10	−29	−9
Deferred and prepaid tax assets	23,000	686,000	−2	−2	−877,000
Other assets	−5	135,000	−6	−307,000	−160,000
Operating lease liabilities	−2	−2	−2	−2	−2
Accounts payable	2	7	864,000	2	−163,000
Accrued expenses and other liabilities	−6	3	2	−314,000	5
Net cash used in operating activities	−157	−119	−97	−105	−68
Proceeds from issuance of ordinary shares and Pre-funded Warrants, net of issuance costs	140	26	145	440,000	155
Proceeds from the exercise of warrants	0	37	0	—	—
Proceeds from the vesting of restricted share units	1,000	0	—	—	—
Payments of withholding tax on stock award	0	−239,000	−265,000	0	0
Proceeds from the issuance of shares under the employee share purchase plan	319,000	365,000	351,000	199,000	0
Proceeds from exercise of options	35,000	221,000	2,000	401,000	2
Net cash provided by financing activities	141	64	174	1	157
Effect of exchange rate changes on cash, cash equivalents and restricted cash	1	194,000	867,000	−25	−6
Net (decrease)/increase in cash, cash equivalents and restricted cash	−15	−55	77	−130	83
Cash paid for interest	3	3	1	0	0
Cash paid for taxes	755,000	1	2	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro